Acura Pharmaceuticals Inc.
10/02/2024 | Press release | Distributed by Public on 10/02/2024 09:16
Financial Obligation Form 8 K
Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
| Date | Principal | Aggregated Principal | ||||||||||
| Original Secured Promissory Note Additional loans to be included: | 11/10/2022 | $ | 2,319,279 | $ | 2,319,279 | |||||||
| Loan #1 | 12/22/2022 | $ | 250,000 | $ | 2,569,279 | |||||||
| Loan #2 | 1/19/2023 | $ | 250,000 | $ | 2,819,279 | |||||||
| Loan #3 | 2/22/2023 | $ | 250,000 | $ | 3,069,279 | |||||||
| Loan #4 | 3/20/2023 | $ | 250,000 | $ | 3,319,279 | |||||||
| Loan #5 | 5/19/2023 | $ | 150,000 | $ | 3,469,279 | |||||||
| Loan #6 | 7/10/2023 | $ | 200,000 | $ | 3,669,279 | |||||||
| Loan #7 | 7/28/2023 | $ | 250,000 | $ | 3,919,279 | |||||||
| Loan #8 | 8/30/2023 | $ | 250,000 | $ | 4,169,279 | |||||||
| Loan #9 | 10/11/2023 | $ | 250,000 | $ | 4,419,279 | |||||||
| Loan #10 | 12/04/2023 | $ | 250,000 | $ | 4,669,279 | |||||||
| Loan #11 | 1/08/2024 | $ | 250,000 | $ | 4,919,279 | |||||||
| Loan #12 | 2/14/2024 | $ | 250,000 | $ | 5,169,279 | |||||||
| Loan #13 | 3/14/2024 | $ | 250,000 | $ | 5,419,279 | |||||||
| Loan #14 | 5/10/2024 | $ | 200,000 | $ | 5,619,279 | |||||||
| Loan #15 | 6/03/2024 | $ | 75,000 | $ | 5,694,279 | |||||||
| Loan #16 | 6/14/2024 | $ | 200,000 | $ | 5,894,279 | |||||||
| Loan #17 | 7/03/2024 | $ | 150,000 | $ | 6,044,279 | |||||||
| Loan #18 | 7/22/2024 | $ | 100,000 | $ | 6,144,279 | |||||||
| Loan #19 | 8/19/2024 | $ | 125,000 | $ | 6,269,279 | |||||||
| Loan #20 | 9/20/2024 | $ | 100,000 | $ | 6,369,279 | |||||||
| Loan #21 | 9/30/2024 | $ | 150,000 | $ | 6,519,279 |
ACURA PHARMACEUTICALS, INC.
| By: | /s/ Robert A. Seiser | |
| Robert A. Seiser | ||
| Senior Vice President & CFO | ||
| Date: September 30, 2024 |